The role of cost-effectiveness analyses in selection of medicines for national insurance schemes and national essential medicines list: Process and country examples
- At: 2006 FIP Congress in Salvadore (Brazil)
- Type: Presentation
- By: WANING, Brenda (Boston University, International Health, Cambridge, United States of America)
Limited resources for medicines require cost considerations be made at all levels of the health care system including national, facility, program, practitioner, and consumer levels. Cost-effectiveness analyses have been widely used by policy makers in many developed countries to guide decisions about medicine coverage. In developing and.. The access to the whole abstract and the presentation file is available to FIP members and to congress participants of that specific congress.